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Abstract
Background: Previous studies suggested that the molecular subtypes were strongly associated with sentinel lymph node
(SLN) status. The purpose of this study was to determine whether molecular subtype classification was associated with non-
sentinel lymph nodes (NSLN) metastasis in patients with a positive SLN.
Methodology and Principal Findings: Between January 2001 and March 2011, a total of 130 patients with a positive SLN
were recruited. All these patients underwent a complete axillary lymph node dissection. The univariate and multivariate
analyses of NSLN metastasis were performed. In univariate and multivariate analyses, large tumor size, macrometastasis and
high tumor grade were all significant risk factors of NSLN metastasis in patients with a positive SLN. In univariate analysis,
luminal B subgroup showed higher rate of NSLN metastasis than other subgroup (P=0.027). When other variables were
adjusted in multivariate analysis, the molecular subtype classification was a determinant of NSLN metastasis. Relative to
triple negative subgroup, both luminal A (P=0.047) and luminal B (P=0.010) subgroups showed a higher risk of NSLN
metastasis. Otherwise, HER2 over-expression subgroup did not have a higher risk than triple negative subgroup (P=0.183).
The area under the curve (AUC) value was 0.8095 for the Cambridge model. When molecular subtype classification was
added to the Cambridge model, the AUC value was 0.8475.
Conclusions: Except for other factors, molecular subtype classification was a determinant of NSLN metastasis in patients
with a positive SLN. The predictive accuracy of mathematical models including molecular subtype should be determined in
the future.
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Introduction
Sentinel lymph node biopsy (SLNB) has been proved to be a
valid method of assessing axillary lymph node status in early breast
cancer patients [1,2], and has been accepted as a standard of care
for early breast cancer patients [3,4]. The axillary lymph node
dissection (ALND) can be omitted when sentinel lymph nodes
(SLNs) are negative. Generally, completion ALND is still needed
for the patients with a positive SLN, and more morbidity would be
carried including lymphoedema, seroma, arm weakness and so on
[5,6]. However, metastases in non-sentinel lymph nodes (NSLN)
were found in about 40% of the patients with positive SLNs [7,8].
Up to now, whether ALND is necessary for the patients with
only SLNs involvement is not very clear. However, many
researchers think that the therapeutic benefit is minimal for those
patients [9–11]. Therefore, it is important to identify patients with
SLNs involvement but without NSLNs metastases. Many clinical
parameters were reported as risk factors of additional disease in
NSLNs, including size of the primary tumor, size of the SLN
metastasis, lymphovascular invasion, proportion of positive SLNs
and so on [10,12]. Furthermore, many mathematical models for
estimation of NSLN metastases have been suggested in those
patients [13–17]. However, the predicted probability of these
models was not always very high.
The molecular subtype classification was firstly reported by
Perou and his colleagues [18]. Different subtypes of breast cancer
were associated with different metastasis pattern [19] and different
survival [20]. The molecular subtype was associated with the
axillary status. Recent studies [21,22] showed that molecular
subtypes based on immunohistochemical (IHC) were strongly
associated with SLN status. To our knowledge, triple negative
breast cancer (estrogen receptor (ER) negative, progesterone
receptor (PR) negative, and HER2 negative) was correlated to
more aggressive behaviors than other subgroups but with less
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hypothesized that the NSLN metastasis is correlated to intrinsic
biological properties in different molecular subtypes regardless of
the size of the primary tumor, grade of primary tumor, and size of
the SLN metastasis.
The Cambridge model [14] was a modified predictive model for
NSLN derived from the Memorial Sloan-Kettering Cancer Center
(MSKCC) nomogram [13], which requires only three variables
(tumor type/grade, maximum size of involved SLN, and
proportion of positive SLNs). Previous studies [10,23] suggested
that the Cambridge model had the advantage of requiring fewer
measurements with a more accurate predictive performance. The
second aim of this study was to determine whether molecular
subtype classification based on IHC can increase the predictive
accuracy of the Cambridge model.
Materials and Methods
Patients
This retrospective study was approved by the ethics committee
of The First Affiliated Hospital with Nanjing Medical University.
Written consent was given by the patients for their information to
be stored in the hospital database and used for research. This
study was also in compliance with the Helsinki Declaration.
We reviewed our database of breast cancer patients who
underwent SLNB from January 2001 through March 2011 in our
hospital. Of these patients, 408 were identified who underwent
complete ALND. In all, data from 130 women with a positive SLN
who underwent ALND were included.
Medical records of all these 130 patients were reviewed by us.
Clinical information collected for this study included age, tumor
size, tumor grade, number of positive SLNs, number of negative
SLNs, NSLN status, lymphovascular invasion, size of largest
metastasis in the SLN, ER, PR, and HER2 status.
The SLNB procedure was performed with blue dye alone, or a
combination with radioisotope. Preoperative SLN imaging was
done on the day before surgery, according to a standard protocol,
with radioisotope injected superficially. This was followed by c
camera imaging. On the day of surgery, the blue dye was injected,
and the area was massaged. Most SLNs in this group were found
along sentinel lymphatic channels (SLCs).
Histology
After the SLNs were successfully dissected, they were sent to the
pathology lab immediately. The metastases of SLNs were detected
by imprint cytology, frozen section, hematoxylin and eosin (H&E)
stain and IHC.
ALND was performed after SLN dissection when metastases
were found in SLNs at intraoperative examinations. All NSLNs
were analyzed with routine H&E stain on a single section of each
node. When the definitive analysis revealed a positive SLN after
the intraoperative examination, the patients were recalled for
ALND in about two weeks. The H&E stain of all positive SLNs
were reviewed by two experienced pathologists, and the maximum
size of the metastasis was obtained. Positive SLNs were divided
into two groups according to the maximum size of the metastasis:
micrometastasis (#2 mm) and macrometastasis (.2 mm).
ER and PR status were determined by IHC. The determination
of HER2 over-expression status was determined according to the
American Society of Clinical Oncology guidelines [24]. According
to different combinations of ER, PR and HER2 status, all patients
were categorized into four subgroups [25] as follows: luminal A,
luminal B, HER2 over-expression, and triple negative.
Statistical analysis
In our study, median, percentiles and range were analyzed for
continuous variables. The candidate explanatory variables in the
univariate and multivariate analyses of NSLN were: age at
diagnosis, primary tumor size, tumor grade, number of SLN
examined, maximum size of SLN metastasis, proportion of positive
SLN, and molecular subtype classification. The patients were
divided into two subgroups for univariate analyses: patients with
NSLN metastasis group and without NSLN metastasis group.
Differences between the two subgroups with regard to above
variables were examined using Fisher’s exact test for unordered
categorical variables and nonparametric rank test for ordinal
categorical variables. A multivariate logistic regression analysis was
performed to determine the probability of having a positive NSLN
and to build a nomogram. The variables for the Cambridge model
in this study were: tumor grade, maximum size of involved SLN,
and proportion of positive SLNs. The molecular subtype classifi-
cation was added to the above three variables to build a new
nomogram. Discrimination was quantified with the area under the
receiver operating characteristic (ROC) curve. In all tests, a two-
sided level of significance of 0.05was applied. Alldata analyses were
carried out using STATA version 10.0 and R software.
Results
A total of 130 invasive breast cancer patients had a positive SLN
and ALND. The median age of these patients was 50 y (range, 28–
78 y). The average number of dissected SLNs was 2.4 (range, 1–7),
and the median number of dissected NSLNs was 15 (range, 3–34).
Of these 130 patients, seventy-six patients (58.46%) had at least
one positive NSLN. Baseline characteristics of these 130 early
breast cancer patients were shown in Table 1.
In the univariate analysis of NSLN metastasis (Table 2), more
large tumors were observed in positive NSLN group than in
negative NSLN group (P=0.046). The proportion of patients with
macrometastasis in SLN was significantly different between the
two groups (57.69% vs 86.67%, P,0.001). Furthermore, tumor
grade between the two groups were significantly different
(P=0.003). The proportion of patients with metastases in all
SLNs in positive NSLN group showed a trend towards higher than
that in negative NSLN group (P=0.081). The age at diagnosis
(P=1.00) and the number of SLN examined (P=0.278) did not
show significant differences between the two groups. Among
molecular subtypes, luminal B subgroup showed the higher rate of
NSLN metastasis than other groups (80.95% vs 53.13%,
P=0.027).
In the multivariate analysis (Table 3), large tumor size
(P=0.013), large size of SLN metastasis (P=0.039), high tumor
grade (P=0.038), and high proportion of positive SLNs (P=0.014)
were all significant factors of NSLN metastasis. Furthermore,
when other variables were adjusted, the molecular subtype
classification was a determinant of NSLN metastasis. Relative to
triple negative subgroup, both luminal A (P=0.047) and luminal B
(P=0.010) subgroups showed a higher risk of NSLN metastasis in
patients with a positive SLN. Otherwise, HER2 over-expression
subgroup did not have a higher risk than triple negative subgroup
(P=0.183).
Of all 130 patients, complete data from 69 patients were
available for the Cambridge model. The discriminative ability of
this model was shown in the ROC curve in Fig. 1. The value of the
area under the curve (AUC) was 0.8095 (95% confidence interval
(CI): 0.7011–0.9179). When the molecular subtype classification
was added to the model, data from 65 patients were available for
our new model. The AUC value was 0.8475 (95% CI: 0.7483–
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However, the 95% CIs overlapped, so no significant difference
existed between the two curves. Furthermore, the relationship
between the observed outcome frequencies and the predicted
probabilities of the two models was shown in Fig. 2.
Discussion
SLNB has been widely used to assess the axillary status for early
breast cancer patients. However, there was no therapeutic purpose
for patients with the only site of regional node disease in the SLN.
Up to now, many risk factors for additional disease in NSLNs were
identified [10,12], including the size for primary tumor, the grade
of primary tumor, the maximum size of positive SLNs, and
lymphovascular invasion. Although ER, PR and HER2 status
were analyzed in several studies [26–29], they were all not risk
factors for NSLN metastasis in patients with a positive SLN.
Table 1. Characteristics of breast cancer patients with
positive sentinel lymph node.
Variable No. (%)
Age, y
#50 71 (54.62%)
.50 59 (45.38%)
Tumor size
T1 52 (40.00%)
T2 68 (52.31%)
T3 6 (4.62%)
NA 4 (3.08%)
Tumor type
Ductal 124 (95.38%)
Others 6 (4.62%)
Lymphovascular invasion
Yes 18 (13.85%)
Others
* 112 (86.15%)
Number of SLN exmanined
1 57 (43.85%)
2 36 (27.69%)
$3 37 (28.46%)
Size of SLN metastasis
Micrometastasis 32 (24.62%)
Macrometastasis 95 (73.08%)
NA 3 (2.31%)
Grade
I 9 (6.92%)
II 38 (29.23%)
III 25 (19.23%)
NA 58 (44.62%)
Molecular subtype
Triple negative 16 (12.31%)
Luminal A 69 (53.08%)
Luminal B 21 (16.15%)
HER2 over-expression 11 (8.46%)
NA 13 (10.00%)
NSLN metastasis
Yes 76 (58.46%)
No 54 (41.54%)
*the data of most patients in this group was not available.
NSLN, non-sentinel lymph node; NA, not available.
doi:10.1371/journal.pone.0035881.t001
Table 2. Univariate analysis of NSLN metastasis.
Variable Negative NSLN Positive NSLN P value
Age, y
#50 29 42 1.00
.50 25 34
Tumor size
T1 27 25 0.046
T2+T3 25 49
Number of SLN examined
1 28 29 0.278
21 1 2 5
$31 5 2 2
Size of SLN metastasis
Micrometastasis 22 10 ,0.001
Macrometastasis 30 65
Grade
I6 3 0.003
II 20 18
III 5 20
Proportion of positive SLN
,1 21 18 0.081
13 3 5 8
Molecular subtype
Luminal B 4 17 0.027*
Luminal A 33 36
HER2 over-expression 5 6
Triple negative 7 9
*P value for luminal B versus others (luminal A, HER2 over-expression and triple
negative).
doi:10.1371/journal.pone.0035881.t002
Table 3. Multivariate analysis of non-SLN metastasis.
Variable OR 95% CI P value
Age 3.63 0.67–19.78 0.136
Tumor size 9.35 1.59–55.08 0.013
Number of SLN examined 1.99 0.78–5.09 0.151
Size of SLN metastasis 9.21 1.12–75.62 0.039
Grade 4.89 1.09–21.84 0.038
Proportion of positive SLN 15.50 1.73–139.16 0.014
Molecular subtype
Triple negative 1 Reference
Luminal A 17.10 1.03–282.61 0.047
Luminal B 60.22 2.69–1350.03 0.010
HER2 over-expression 9.50 0.35–260.76 0.183
doi:10.1371/journal.pone.0035881.t003
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classification was associated with SLN status. Compared with
ER negative and HER2 negative subtype breast cancer, other
subtypes showed a higher risk of SLN metastasis in multivariate
logistic regression model. However, the relationship between the
molecular subtype classification and NSLN status in patients with
a positive SLN was still not clear. This study found that the
molecular subtype classification was associated with NSLN
metastasis in patients with a positive SLN. In our multivariate
analysis, relative to triple negative breast cancer, both luminal A
and Luminal B subtypes of breast cancer had a higher risk of
NSLN metastasis; HER2 over-expression subtype breast cancer
had a higher risk of NSLN metastasis, but no significant difference
was reached. All these studies suggested that triple negative breast
cancer may be associated with more aggressive behaviors but with
less lymph node metastasis. Future studies with large sample size
were still needed to validate our interesting findings.
Several models were created to predicting the probability of
NSLN metastasis, including the MSKCC nomogram [13], the
Mayo model [17], the Stanford Online Calculator model [15], the
Cambridge model [14] and so on. The MSKCC model, which
required nine variables, was validated in more than 15 studies
[10,30]. However, the AUC value from this model was not very
high, ranging from 0.63 to 0.76. Previous studies [10,30] suggested
that the Cambridge model and Stanford model had the similar
accurate predictive performance with the MSKCC and Mayo
models, but required fewer measurements. A recent study [23]
suggested that the Cambridge model had a highest AUC value out
of all these models but required only three variables. Due to the
advantages of the Cambridge model, it was selected for this study.
The AUC value of the Cambridge model was 0.8095 in the
present study and patient population, which seemed higher than
that of previous studies. Small sample size in our study may
contribute to this high AUC value of the Cambridge model. When
the molecular subtype classification was added to the model, the
AUC value was 0.8475 for this new model. Our new model may
have a more accurate predictive performance, and future study
with large sample size was needed to validate our finding.
Limitations
On the other hand, some limitations still exist in the present
study. First, most data of lymphovascular invasion, required in
MSKCC model, was not available. Although the Cambridge
model and our model did not require this variable, it should be
considered in future studies. Second, the NSLNs were examined
by routine histopathological analysis only, and the status of NSLNs
may be underestimated. Third, the complete data used in
Cambridge model and our model were from less than 70 patients.
Therefore, future studies with large sample size should be taken.
In conclusion, in patients with a positive SLN, large tumor size,
high tumor grade, macrometastasis in SLN, and high proportion
of positive SLN were all independent predictors of NSLN
involvement. When other variables were adjusted, the molecular
subtype classification was associated with NSLN metastasis.
Although our model had a more accurate predictive performance
than the Cambridge model, no significant difference was found
between the models in this study. Future prospective studies should
be taken to validate our interesting findings.
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